Chondroitin-ACOS, ointment 5% 50 g

Pharmacotherapeutic group: Tissue regeneration stimulator

ATC code: M01AX25

Pharmacodynamics:

Chondroitin sulfate is a high molecular weight mucopolysaccharide slows bone tissue resorption and reduces calcium loss. Improves calcium-phosphorus metabolism in cartilage tissue. Accelerates the process of its restoration inhibits the process of degeneration of cartilage and connective tissue. Inhibits enzymes that cause cartilage tissue damage stimulates the synthesis of glycosaminoglycans promotes the regeneration (restoration) of the joint capsule and cartilage surfaces increases production of intra-articular fluid. Due to its structural proximity to heparin, it prevents the formation of fibrin clots in the synovial and subchondral microcirculatory system. Reduces pain and increases the mobility of affected joints. Slows the progression of osteoarthritis.

Dimethylsulfoxide contained in the ointment has anti-inflammatory analgesic and fibrinolytic effect promotes better penetration of chondroitin sulfate through cell membranes.

Pharmacokinetics:

According to the data obtained in experimental studies with mice using radiolabeled 3H-chondroitin sulfate the absorption rate of chondroitin sulfate is 14%.

The dimethyl sulfoxide in the ointment promotes better penetration of chondroitin sulfate through cell membranes into the deep tissues.

Chondroitin sulfate enters the joint after application of the ointment on the skin with maximum concentration reached after 30 min followed by biphasic elimination of the drug from the cartilage tissue. Completion of the fast phase of excretion occurs 1 hour after application. Retention time of the drug in the joint is 5 hours.

Indications

Degenerative-dystrophic diseases of the joints and spine – osteoarthritis with predominant damage to large joints, intervertebral osteochondrosis.

Pharmacological effect

Pharmacotherapeutic group: Tissue regeneration stimulator

ATX code: M01AX25

Pharmacodynamics:

Chondroitin sulfate, which is a high-molecular mucopolysaccharide, slows down bone resorption and reduces calcium loss. Improves phosphorus-calcium metabolism in cartilage tissue. Accelerates the processes of its restoration and inhibits the processes of degeneration of cartilage and connective tissue. Suppresses enzymes that cause damage to cartilage tissue, stimulates the synthesis of glycosaminoglycans, promotes regeneration (restoration) of the joint capsule and cartilaginous surfaces of joints, increases the production of intra-articular fluid. Due to its structural proximity to heparin, it prevents the formation of fibrin blood clots in the synovial and subchondral microvasculature. Reduces pain and increases mobility of affected joints. Slows down the progression of osteoarthritis.

Dimethyl sulfoxide, which is part of the ointment, has an anti-inflammatory analgesic and fibrinolytic effect and promotes better penetration of chondroitin sulfate through cell membranes.

Pharmacokinetics:

In accordance with data obtained in experimental studies on mice using radiolabeled 3H-chondroitin sulfate, the absorption rate of chondroitin sulfate is 14%.

Dimethyl sulfoxide, which is part of the ointment, promotes better penetration of chondroitin sulfate through cell membranes deep into tissues.

After applying the ointment to the skin, chondroitin sulfate enters the joint, reaching a maximum concentration after 30 minutes and subsequent two-phase removal of the drug from the cartilage tissue. Completion of the rapid elimination phase occurs 1 hour after application. The retention time of the drug in the joint is 5 hours.

Special instructions

Avoid getting the ointment on mucous membranes and open wounds.

Do not use the drug without consulting a doctor under the age of 18.

Impact on the ability to drive vehicles. Wed and fur.:

Chondroitin-AKOS ointment does not affect the ability to drive vehicles and engage in potentially hazardous activities that require increased concentrated attention and speed of psychomotor reactions.

Active ingredient

Chondroitin sulfate

Composition

Per 100 g:

Active ingredient: sodium chondroitin sulfate (in terms of dry matter) – 5.0 g;

Excipients: dimethyl sulfoxide (dimexide), lanolin (lanolin anhydrous), petroleum jelly (medical petroleum jelly), purified water.

Pregnancy

During pregnancy and during breastfeeding (lactation), Chondroitin-AKOS ointment is prescribed only after consulting a doctor and the duration of treatment is determined by the doctor with caution.

Contraindications

Hypersensitivity – violation of the integrity of the skin at the sites of intended application.

With caution:

Do not use Chondroitin-AKOS ointment without consulting a doctor during pregnancy and lactation (breastfeeding).

Age up to 18 years.

Side Effects

In rare cases, allergic reactions are possible and the drug should be discontinued.

If you notice any other side effects not listed in the instructions, tell your doctor.

Interaction

There have been no cases of negative drug interactions when prescribing the ointment during therapy with other drugs included in generally accepted treatment regimens for degenerative diseases of the joints and spine.

Overdose

When using Chondroitin-AKOS ointment externally, an overdose is unlikely (due to the lack of systemic absorption of the drug). To date, no cases of overdose of Chondroitin-AKOS ointment have been reported.

Storage conditions

At a temperature not exceeding 25 °C.

Keep out of the reach of children.

Shelf life

5 years.

Do not use after expiration date.

Manufacturer

Sintez, Russia